血管紧张素Ⅱ受体及其受体1与肿瘤新生血管生成关系的研究进展  

Progress in relationship between angiotensin Ⅱ receptor with angiotensin Ⅱ type 1 receptor and angiogenesis of tumor

作　　者：郭琳[1] 梁单[2] 韩颖霞 葛艳[1] Guo Lin Liang Dan Han Yingxia Ge Yan(Troops of 93253 Unit of Chinese People＇s Liberation Army , Liaoning Dalian 116023, China Troops of 95935 Unit of Chinese People＇s Liberation Army, Heilongjiang Shuangcheng 150111, China.)

机构地区：[1]中国人民解放军93253部队 [2]中国人民解放军95935部队

出　　处：《现代肿瘤医学》2016年第23期3855-3859,共5页Journal of Modern Oncology

摘　　要：血管紧张素Ⅱ(ATⅡ)是肾素-血管紧张素系统(RAS)产生的一种多功能活性多肽,其主要作用于血管紧张素1受体(AT1R)调节血压。近年来,研究表明在大多数常见的肿瘤细胞上均存在AT1R,并且AT1R的表达数量及程度与肿瘤的恶化程度和是否转移密切相关,这种现象与AT1R介导肿瘤新生血管生成增加有关。本文阐述了在常见肿瘤细胞及分子水平上AT1R的表达情况,以及其对肿瘤生长与转移的影响,并对目前ATⅡ-AT1R抑制剂单独或联合用药对肿瘤影响的相关研究进行了探讨。Angiotensin Ⅱ（ ATⅡ） is a bioactive peptide of the renin- angiotension system（ RAS）,which adjusts blood pressure via angiotensin Ⅱ type 1 receptor（ AT1R）. Recently,many studies examined AT1 R expression in common human tumor. AT1 R expression shows direct correlation with tumor progression and distant metastasis. This phenomenon is related to angiogenesis of tumor by AT1 R. The pressent study discussed the AT1 R expression on a cellular and molecular level,as well as the effect on tumor growth and metastasis. Furthermore,we considered the ATⅡ- AT1 R blocker on tumor tissue in alone or combination with medication.

关 键 词：血管紧张素Ⅱ 血管紧张素Ⅱ1型受体 肿瘤 癌 ATⅡ-AT1R抑制剂 

分 类 号：R730.231[医药卫生—肿瘤]